Folic Active® capsules

About Folic Active® capsules

Food supplement with active folate (5–MTHF).
Folate (folic acid) contributes to normal amino acids synthesis and normal blood formation. Supplemental folic acid intake increases maternal folate status. Low maternal folate status is a risk factor in the development of neural tube defects in the developing foetus.
Folate (folic acid) contributes to maternal tissue growth during pregnancy.

Intended use - for who and when?

The target population is women of childbearing age. Beneficial effect is obtained with a supplemental folic acid daily intake of 400 μg for at least one month before and up to three months after conception. Neural tube defects in the developing foetus have multiple risk factors, changing one of these risk factors may or may not have a beneficial effect.

Quatrefolic ®

Quatrefolic ® is an innovative substance that represents the fourth generation of folate with improved bioavailability.
Quatrefolic ® is a glucosamine salt of (6S) -5-methyltetrahydrofolate and is structurally analogous to the reduced and active form of folic acid. Folate deficiency is one of the most common vitamin deficiencies. In case of inadequate intake of folate with food, supplementation is recommended.

Folic acid

Main dietary sources include primarily green leafy vegetables, followed by legumes, citrus fruits, whole grains and meat.

 

Folate contributes to normal amino acid synthesis and blood formation.

 

Folate has a role in the cell division process, therefore it is especially important in the period of accelerated cell division and growth, like that of childhood and pregnancy.

 

Folate contributes to maternal tissue growth during pregnancy.

 

Supplemental folic acid intake increases maternal folate status. Low maternal folate status is a risk factor in the development of neural tube defects in the developing foetus.

 

The target population is women of child-bearing age and the beneficial effect is obtained with a supplemental folic acid daily intake of 400 μg for at least one month before and up to three months after conception.